The Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD 21287;
Translational Cancer Research, Department of Laboratory Medicine, Lund University, 223 81 Lund, Sweden.
Proc Natl Acad Sci U S A. 2021 Feb 16;118(7). doi: 10.1073/pnas.2020838118.
We present a unifying theory to explain cancer recurrence, therapeutic resistance, and lethality. The basis of this theory is the formation of simultaneously polyploid and aneuploid cancer cells, polyaneuploid cancer cells (PACCs), that avoid the toxic effects of systemic therapy by entering a state of cell cycle arrest. The theory is independent of which of the classically associated oncogenic mutations have already occurred. PACCs have been generally disregarded as senescent or dying cells. Our theory states that therapeutic resistance is driven by PACC formation that is enabled by accessing a polyploid program that allows an aneuploid cancer cell to double its genomic content, followed by entry into a nondividing cell state to protect DNA integrity and ensure cell survival. Upon removal of stress, e.g., chemotherapy, PACCs undergo depolyploidization and generate resistant progeny that make up the bulk of cancer cells within a tumor.
我们提出了一个统一的理论来解释癌症复发、治疗耐药性和致命性。该理论的基础是同时形成多倍体和非整倍体癌细胞,即多倍体非整倍体癌细胞(PACCs),它们通过进入细胞周期阻滞状态来避免全身治疗的毒性作用。该理论与经典相关的致癌突变已经发生的情况无关。PACCs 通常被视为衰老或垂死的细胞而被忽视。我们的理论指出,治疗耐药性是由 PACC 的形成驱动的,这种形成是通过进入多倍体程序来实现的,该程序允许非整倍体癌细胞将其基因组含量翻倍,然后进入非分裂细胞状态以保护 DNA 完整性并确保细胞存活。在去除压力(例如化疗)后,PACCs 经历去多倍化并产生耐药后代,这些后代构成肿瘤内大部分癌细胞。